All In Biotech

Drug Trial Radar · NCT00344968

Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema

A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 μg/Day and ASI-001B 0.2 μg/Day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects With Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: May 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 956 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

956

Actual

Start

Sep 2007

Primary completion

Dec 2009

Study completion Dec 2010

Sponsor

Lead sponsor
Alimera SciencesIndustry
Sponsor type
Industry
First posted
Jun 27, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of an intravitreal insert of fluocinolone acetonide for the treatment of diabetic macular edema.

Conditions

  • Diabetic Macular Edema

Interventions

  • fluocinolone acetonideDrug

    0.5 mg fluocinolone acetonide intravitreal insert

  • Fluocinolone AcetonideDrug

    0.2 mg fluocinolone acetonide intravitreal insert

  • Standard of care laser photocoagulationProcedure

    Laser photocoagulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual AcuityTime frame: 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.